Australia's Argenica Therapeutics tumbles as FDA halts stroke drug application

ReutersJun 10, 2025 1:24 AM

View all comments（0）



Biotech firm Argenica Therapeutics shares AGN.AX fall 10.8% to A$0.7, lowest level since May 1

Stock poised for weakest session since early April, if trends sustain

U.S. FDA holds co's Investigational New Drug Application, finding its data "inadequate" for clinical trials of acute ischaemic stroke (AIS) drug

Co says it will provide additional data to the FDA

AIS patients suffer from decreased blood flow to the brain

Trading volume at more than 113,000 shares vs 30-day avg of around 100,000 shares

Stock up 11.1% YTD, including current session's moves

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Samsung’s Largest Strike in History: Can SK Hynix and Micron Sit Back and Reap the Benefits?

TradingKey - On May 21, 61,000 union members at Samsung Electronics will launch an 18-day general strike, following a 93.1% approval vote. Government mediation between labor and management has collapsed.

Inflation 'High Fever' Fails to Stop Rally? BTC Temporarily Loses 80,000 Mark, But Arthur Hayes Sees Peak of $126,000

Higher-than-expected CPI data triggered a Bitcoin drop below $80,000, but the BitMEX co-founder remains staunchly bullish on BTC.

Today’s Market Recap: US Inflation Hits 3-Year Peak as Market Braces for Trump’s China Visit and Fed Leadership Shift

April inflation hit a three-year peak of 3.8%, pressuring the Nasdaq and tech stocks. Markets are further braced by Kevin Warsh’s Fed Chair confirmation, the maintenance of Trump’s 10% global tariffs, and a high-profile U.S. business delegation preparing for a strategic state visit to China.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools